908 Devices and Cellares Collaborate to Integrate In-line Monitoring of Bioprocess Parameters into the Cell Shuttle, Cellares’ Fully Integrated Cell Therapy Manufacturing Platform
- None.
- None.
Insights
The collaboration between 908 Devices Inc. and Cellares represents a strategic move in the biotechnology and cell therapy manufacturing industry. From a market research perspective, integrating in-line monitoring systems like MAVERICK into Cellares' Cell Shuttle system could potentially disrupt the cell therapy manufacturing market. It addresses a critical need for efficiency and cost-effectiveness in the production of cell therapies, which are often hampered by high costs and complex processes.
The ability of the MAVERICK system to deliver actionable process parameters or direct process control actions without the need for extensive modeling or development is significant. It suggests a reduction in time-to-market for cell therapies and could lead to competitive advantages for both 908 Devices and Cellares. The mention of a 90% reduction in labor and facility size and a tenfold increase in production capacity is particularly noteworthy, as it suggests a substantial improvement over current industry standards.
From a financial standpoint, the partnership could have meaningful implications for the revenue streams and valuation of both 908 Devices and Cellares. The integration of MAVERICK technology into the Cell Shuttle system could lead to increased demand for 908 Devices' analytical tools, particularly if the collaboration proves successful in enhancing cell therapy manufacturing efficiency. Furthermore, the scalability of Cellares' platform implies that if adopted widely, it could generate substantial cost savings for cell therapy producers, potentially expanding the market for their services.
Investors should monitor the adoption rate of the integrated system and any resulting financial metrics, such as reductions in cost of goods sold (COGS) for cell therapies. Additionally, the collaboration could attract attention from larger pharmaceutical companies seeking to improve their own manufacturing processes, potentially leading to further strategic partnerships or even acquisition interest.
In the biotech industry, the application of Raman spectroscopy for bioprocess control is an emerging trend that enhances the quality and consistency of biologic products. The MAVERICK system's de novo models for processing Raman spectra represent a technological advancement that could set new standards for in-line process monitoring. By providing real-time data and enabling immediate corrective action, this technology could significantly mitigate risks associated with cell culture, such as contamination and variability in product quality.
The mention of the Cell Shuttle's capability to support both autologous and allogeneic cell therapy processes and most cell therapy modalities indicates a broad applicability of the technology, which is important as the cell therapy field is rapidly expanding and diversifying. The potential impact on patient outcomes cannot be overstated, as improved manufacturing processes can lead to more reliable and timely availability of cell therapies for various diseases.
908 Devices is integrating its optical in-line analyzer, MAVERICK, the first turn-key device to utilize Raman spectroscopy for bioprocess control, with no modeling or development required. MAVERICK’s purpose-built de novo models automatically process Raman spectra from a wide variety of culture media types and cell lines, delivering actionable process parameters or direct process control actions. The company is adapting its MAVERICK device to be integrated into the Cell Shuttle system.
“In-line analysis provides real-time monitoring of the cell culture process, allowing for immediate corrective action. It also maintains sample integrity, reduces contamination risk, and improves product quality,” said Christopher D. Brown, PhD, Chief Product Officer and Co-founder, 908 Devices. “We’re very proud to partner with Cellares to accelerate access to life-saving cell therapies.”
Cellares’ Cell Shuttle supports both autologous and allogeneic cell therapy processes and most cell therapy modalities. The Cell Shuttle platform integrates all the technologies required for all unit operations and is successfully running CAR-T cell therapy processes with true walk-away, end-to-end automation. Cellares’ Cell Shuttle reduces labor and facility size required by
“We are pleased to announce our collaboration with 908 Devices,” said Daniele Malleo, PhD, Cellares VP of Research and Development. “The integration of the 908’s MAVERICK Raman Spectrometer into Cellares’ fully automated, closed end-to-end cell therapy manufacturing platform will enable real-time process control of key cellular parameters, enhancing the efficiency and safety of cell therapy production while significantly reducing costs. This collaboration is a testament to our vision of making advanced cell therapies more accessible and affordable, ultimately accelerating the delivery of these critical treatments to patients who need them.”
About 908 Devices
908 Devices is revolutionizing chemical and biochemical analysis with its simple handheld and desktop devices, addressing critical-to-life applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in life sciences research, bioprocessing, pharma/biopharma, forensics and adjacent markets. The Company is headquartered in the heart of
About Cellares
Cellares is the first Integrated Development and Manufacturing Organization (IDMO) and takes an Industry 4.0 approach to mass manufacturing the living drugs of the 21st century. The company is both developing and operating integrated technologies for cell therapy manufacturing to accelerate access to life-saving cell therapies. The company's Cell Shuttle integrates all the technologies required for the entire manufacturing process in a flexible and high-throughput platform that delivers true walk-away, end-to-end automation. Cell Shuttle is being deployed in Cellares' Smart Factories around the world to meet total patient demand for cell therapies at global scale. Partnering with Cellares enables academics, biotechs, and pharma companies to accelerate drug development and scale out manufacturing, lower process failure rates, lower manufacturing costs, and meet global patient demand.
The company is headquartered in
For more information about Cellares, please visit cellares.com.
Forward Looking Statements for 908 Devices
This press release includes “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding the expected uses and capabilities of the Company’s products. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on management’s current expectations and involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including the risks outlined under “Risk Factors” and elsewhere in the Company’s filings with the Securities and Exchange Commission which are available on the SEC's website at www.sec.gov. Additional information will be made available in the Company’s annual and quarterly reports and other filings that it makes from time to time with the SEC. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240229838986/en/
908 Devices Media Contact:
Barbara Russo
brusso@908devices.com
908 Devices Investor Contact:
Carrie Mendivil
IR@908devices.com
Cellares Media Contact:
cellares@consortpartners.com
Source: 908 Devices Inc.
FAQ
What is the collaboration between 908 Devices and Cellares about?
What is 908 Devices' MAVERICK device?
How does the integration of MAVERICK into Cellares' Cell Shuttle system benefit cell therapy manufacturing?
What are the advantages of in-line analysis in cell culture processes?
How does Cellares' Cell Shuttle platform improve cell therapy manufacturing processes?
